Sanofi's Drug for Rare Lung Disease Surpasses Standard Treatment in Trial

• Efdoralprin alfa raised AAT protein levels by 24.1 micromolar at week 32 versus 7.6 micromolar for weekly standard therapy, with patients maintaining normal AAT levels throughout the study
• The therapy requires dosing only every three weeks compared to weekly for standard plasma-derived treatments, potentially easing treatment burden on patients
• Sanofi acquired the drug through its 2024 Inhibrx deal worth $2.2 billion following pipeline setbacks, as investors seek growth drivers beyond Dupixent

Summary: Sanofi's Rare Lung Disease Drug Outperforms Standard Treatment

French pharmaceutical giant Sanofi announced positive trial results for efdoralprin alfa, an experimental therapy for a genetic form of lung disease, showing superiority over standard care. The drug was acquired through Sanofi's $2.2 billion Inhibrx deal in 2024.

Key Trial Results:

In a 97-patient head-to-head study presented at the American Thoracic Society meeting in Orlando, efdoralprin alfa demonstrated significantly better outcomes:

• Raised AAT (alpha-1 antitrypsin) protein trough levels by 24.1 micromolar at week 32
• Standard weekly plasma-derived therapy achieved only 7.6 micromolar
• Patients maintained normal AAT levels throughout the study versus less than half the time for standard therapy patients

Market Opportunity:

Sanofi estimates approximately 235,000 people have this condition globally. The company sees growth potential in both switching existing patients from standard therapy and identifying undiagnosed patients.

Competitive Advantages:

• Less frequent dosing: every three weeks versus weekly for standard treatment, reducing patient burden
• Produced using recombinant technology rather than plasma-derived methods, potentially easing dependence on donated plasma

Strategic Context:

This development is crucial for Sanofi as investors seek evidence of pipeline strength beyond Dupixent, the company's top-selling drug. The trial follows previous pipeline setbacks in 2023 and comes as new CEO Belén Garijo works to improve R&D productivity. The study initially met its main goals in October, with detailed data now confirming the therapy's effectiveness in treating AAT deficiency, which can cause lung and liver damage.